Related references
Note: Only part of the references are listed.A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitors-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention
Spencer C. Wei et al.
CANCER DISCOVERY (2021)
Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy
Yang Liu et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2020)
T Cell Costimulation Blockade Blunts Age-Related Heart Failure
Elisa Martini et al.
CIRCULATION RESEARCH (2020)
Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy
Yan Zhang et al.
CELL RESEARCH (2019)
Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis
Joe-Elie Salem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
Xuexiang Du et al.
CELL RESEARCH (2018)
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Xuexiang Du et al.
CELL RESEARCH (2018)
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Javid J. Moslehi et al.
LANCET (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Miguel F. Sanmamed et al.
CELL (2018)
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N. Amaria et al.
NATURE MEDICINE (2018)
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Christian U. Blank et al.
NATURE MEDICINE (2018)
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D. Hellmann et al.
LANCET ONCOLOGY (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
T cell costimulation blockade blunts pressure overload-induced heart failure
Marinos Kallikourdis et al.
NATURE COMMUNICATIONS (2017)
Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma
Yago Pico de Coana et al.
ONCOTARGET (2017)
Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity
Marion Escudier et al.
CIRCULATION (2017)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Lucie Heinzerling et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy
Bernice Lo et al.
SCIENCE (2015)
Exposure-Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma
Yan Feng et al.
CLINICAL CANCER RESEARCH (2013)
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
Yannick Bulliard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Long-Term Safety and Efficacy of Abatacept in Children With Juvenile Idiopathic Arthritis
Nicolino Ruperto et al.
ARTHRITIS AND RHEUMATISM (2010)
B7 Blockade Alters the Balance between Regulatory T Cells and Tumor-reactive T Cells for Immunotherapy of Cancer
Penghui Zhou et al.
CLINICAL CANCER RESEARCH (2009)
Abatacept in children with juvenile idiopathic arthritis:: a randomised, double-blind, placebo-controlled withdrawal trial
Nicolino Ruperto et al.
LANCET (2008)
B7-deficient autoreactive T cells are highly susceptible to suppression by CD4+CD25+ regulatory T cells
Kenneth F. May et al.
JOURNAL OF IMMUNOLOGY (2007)
Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies
KD Lute et al.
BLOOD (2005)
Costimulation blockade with belatacept in renal transplantation
F Vincenti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept - Twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial
JM Kremer et al.
ARTHRITIS AND RHEUMATISM (2005)
Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-lg with potent immunosuppressive properties
CP Larsen et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig
JM Kremer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
